Get the Stockscreener App
4.325
3.05%
0.145
Prime Medicine Inc stock is traded at $4.325, with a volume of 1.45M.
It is up +3.05% in the last 24 hours and up +23.07% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$4.18
Open:
$4.31
24h Volume:
1.45M
Relative Volume:
0.39
Market Cap:
$780.71M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-1.9931
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
+10.74%
1M Performance:
+23.07%
6M Performance:
+2.32%
1Y Performance:
+42.17%
1-Day Range:
$4.25
$4.56
1-Week Range:
$3.8225
$4.70
52-Week Range:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.325 | 754.53M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.94 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.19 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.84 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.23 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.08 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Prime Medicine (NASDAQ:PRME) Shares Down 5.6%What's Next? - MarketBeat
Prime Medicine (NYSE:PRME) Trading Down 5.5%What's Next? - MarketBeat
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Prime Medicine (NASDAQ:PRME) Shares Up 10.5%Here's Why - MarketBeat
Prime Medicine (NYSE:PRME) Shares Up 12.4%Time to Buy? - MarketBeat
Should I trade or invest in Prime Medicine IncJuly 2025 Highlights & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Targets Report: Is NEOV in accumulation or distribution phaseGap Down & Weekly Breakout Stock Alerts - baoquankhu1.vn
How Prime Medicine Inc. stock reacts to bond yieldsEarnings Trend Report & Long-Term Safe Return Strategies - bollywoodhelpline.com
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 7.9%Should You Sell? - MarketBeat
Prime Medicine (NYSE:PRME) Trading Down 5.7%What's Next? - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 8.4%Should You Buy? - MarketBeat
Prime Medicine updates corporate strategy for Prime Editing platform - TipRanks
Prime Medicine, Inc. Updates on Prime Editing Developments - TradingView
What technical charts say about Prime Medicine Inc. stock2025 Market Overview & Verified Chart Pattern Signals - Улправда
Is Prime Medicine Inc. stock a safe buy before earningsJuly 2025 Outlook & Technical Entry and Exit Tips - Улправда
How Prime Medicine Inc. stock benefits from tech adoptionWeekly Market Summary & Weekly Return Optimization Alerts - ulpravda.ru
What hedge fund activity signals for Prime Medicine Inc. stockIndex Update & AI Based Buy/Sell Signal Reports - ulpravda.ru
Prime Medicine initiated with an outperform at LifeSci Capital - MSN
Los Angeles Daily NewsPrime Medicine, Inc.Common Stock (Nasdaq:PRME) Stock Quote - FinancialContent
Prime Medicine (NYSE:PRME) Trading 7.5% HigherWhat's Next? - MarketBeat
How Prime Medicine Inc. stock reacts to oil pricesBullish Engulfing Patterns & High Profit Trading Alerts - Улправда
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
WaterWorldPrime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Prime Medicine, Inc. (PRME) announces NEJM publication of PM359 data - MSN
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond - Seeking Alpha
Prime Medicine (NYSE:PRME) Trading Down 3.3%Here's What Happened - MarketBeat
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases - Insider Monkey
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data - Insider Monkey
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 3.8%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 4.2%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Prime Medicine (PRME) with Outperform Recommendation - Nasdaq
Lifesci Capital Begins Coverage on Prime Medicine (NYSE:PRME) - MarketBeat
LifeSci Capital Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $6 - 富途牛牛
Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease - TipRanks
Prime Medicine initiated with an Outperform at LifeSci Capital - TipRanks
LifeSci Initiates Prime Medicine at Outperform With $6 Price Target - marketscreener.com
Prime Medicine Earnings Notes - Trefis
Prime Medicine, Inc.(NasdaqGM: PRME) added to S&P Biotechnology Select Industry Index - marketscreener.com
Prime Medicine announces NEJM publication of PM359 data - MSN
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: How Prime Medicine Inc. stock reacts to oil pricesWatch List & Safe Entry Trade Reports - Улправда
Risks Report: Why Prime Medicine Inc. stock remains resilient2025 Market Trends & Real-Time Buy Signal Notifications - Улправда
Why Prime Medicine Inc. stock remains resilientTrade Exit Summary & Weekly High Return Stock Forecasts - Улправда
Can Prime Medicine Inc. stock hit record highs againJuly 2025 News Drivers & Weekly High Conviction Ideas - Улправда
Can Prime Medicine Inc. stock withstand economic slowdownTrade Signal Summary & Weekly Top Gainers Alerts - Улправда
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
2.05%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):